THE REAL STORY
BEHIND RECOMP HEALTH.
Ben Morris
Founder · GLP-1 user · Ongoing journey
Recomp Health was not designed from theory. It was built from a personal GLP-1 journey — DEXA scans, blood panels, lean mass tracking, nutritional gaps, and the hard lessons that a scale alone would never have revealed.
Section 1 — Origin
WHY RECOMP HEALTH EXISTS.
When GLP-1 treatment started, the tools available were a bathroom scale, a general calorie tracking app, and quarterly GP check-ins focused on weight and HbA1c. That was standard of care. That was the ceiling.
What was needed — and didn't exist in one place — was a way to track what was actually changing. Not just weight. Lean mass. Fat distribution. Nutritional status. Injection timing patterns. Biomarkers that GLP-1 users are at elevated risk of depleting.
The clinical trial literature was clear: without structured resistance training and adequate protein intake, a significant proportion of weight lost on GLP-1 medications comes from lean mass. The evidence existed. The tools to act on it in daily life did not.
Recomp Health was built to close that gap — not because the journey was finished, but because the tools were needed while it was still underway.
What scale weight cannot tell you
Section 2 — The journey so far
THE JOURNEY SO FAR.
A documented timeline of GLP-1 treatment, DEXA scans, bloodwork, nutrition adjustments, and training evolution. Upcoming entries are placeholders for future data as the journey continues.
GLP-1 treatment begins
Started GLP-1 medication under GP supervision. No specialist body composition tracking existed. Scale weight was the only feedback available. That was the gap.
First DEXA scan — establishing the baseline
The first DEXA scan provided a proper starting point: fat mass, lean mass, visceral fat area, and appendicular lean mass index. The numbers were precise in a way no scale could match.
First blood panel — unexpected findings
Routine bloodwork returned with two unexpected flags. B12 was below optimal range. Iron and ferritin were also low. Neither was visible on the scale, and neither was causing obvious symptoms. Without tracking, both would have gone unaddressed.
Protein intake — the gap nobody warned about
GLP-1 appetite suppression made it easy — even pleasant — to eat significantly less. But tracking revealed that protein was falling well below the 1.6g/kg lean mass target that the research literature supports for lean mass preservation. Appetite suppression and adequate protein intake were in direct conflict.
Strength training reprioritised
GLP-1 fatigue and appetite changes made it tempting to reduce training volume. The DEXA baseline and early lean mass tracking made the stakes of that decision visible. Training was restructured around progressive resistance 3× per week, with key compound lifts logged consistently.
Second DEXA scan — first comparative data
The second scan provided the first meaningful comparison. Fat mass had decreased significantly. Lean mass was largely preserved. The combination of protein targets, structured resistance training, and continuous tracking was producing the recomposition pattern — not just weight loss.
Second blood panel — monitoring the corrections
Follow-up bloodwork to assess B12 and iron supplementation response. Both markers had improved. Ongoing monitoring remained important — GLP-1 reduced food volume creates a sustained risk of micronutrient deficiency that a single supplement fix does not permanently resolve.
Third DEXA scan — full journey data
The third scan completed the documented phase of the journey. −24 kg fat mass. 92% lean mass preserved. Visceral fat area reduced significantly. The combination of active body composition monitoring, structured resistance training, protein targeting, and biomarker awareness produced measurably different outcomes than scale-only tracking would have allowed.
The platform is built from the gaps
The tools used throughout this journey — injection tracking, lean mass trends, biomarker logging, nutrition targets calibrated to GLP-1 physiology — were assembled from separate apps and manual records. Recomp Health was built to put them in one place, evidence-backed, and designed for this specific context.
Next DEXA scan planned
The journey continues. Regular DEXA scanning remains part of the ongoing monitoring protocol. Results will be published here as part of the continuing data record.
Ongoing biomarker monitoring
B12, iron, ferritin, HbA1c, lipid panel, testosterone, and vitamin D will continue to be tested regularly. All results will be shared as the monitoring record grows.
Section 3 — Below the surface
WHAT THE SCALE COULDN'T SHOW.
Vitamin B12
B12 deficiency is common in GLP-1 users because reduced food volume and changes in gastric acid production impair absorption. Blood panel revealed a below-optimal result that had no obvious symptoms. It would not have been identified without testing.
Lesson: reduced food volume ≠ adequate micronutrient intake.
Iron and ferritin
Iron status was also flagged — ferritin below optimal range. The connection to reduced dietary intake, particularly from red meat, was direct. The practical impact was subtle: slightly reduced training capacity and slower recovery. Not visible on a scale.
Lesson: energy and performance issues may have a biomarker explanation.
Protein intake
GLP-1 significantly suppresses appetite. The effect is useful for fat loss but creates a specific risk: it becomes easy to severely under-eat protein without feeling hungry. Tracking revealed consistent protein deficits relative to lean mass preservation targets. The body doesn't signal the difference.
Lesson: GLP-1 appetite suppression and adequate protein are in direct conflict without active management.
Lean mass trends
DEXA scans made lean mass visible in a way that smart scale BIA alone cannot match. More importantly, tracking lean mass over time — between scans — via weekly BIA provided early signals when the trend shifted. That allowed training and nutrition to be adjusted before DEXA confirmed the problem.
Lesson: trend data is more actionable than single-point measurements.
Recovery and performance
Low B12 and iron were contributing to recovery deficits that felt like normal GLP-1 fatigue. Without separating the causes — GLP-1 adaptation vs. nutritional deficiency — the response would have been wrong. Data allowed the correct explanation to be identified.
Lesson: fatigue during GLP-1 treatment has multiple potential causes. Biomarkers identify which.
Strength deficits
Compound lift performance declined early in the GLP-1 journey — expected during a caloric deficit. DEXA-validated lean mass data allowed training volume and intensity to be calibrated against what was actually being preserved, not just perceived effort. The numbers removed guesswork.
Lesson: strength changes during GLP-1 treatment are more informative when framed against body composition data.
Section 4 — Practical lessons
LESSONS LEARNED.
These are observations from one person's documented GLP-1 journey — not clinical recommendations. They are shared for educational context only. Individual circumstances differ. Always work with your own healthcare team.
Test before you assume.
B12 and iron deficiency had no dramatic symptoms. Without a blood panel at the right time, both would have gone unaddressed for months. Routine testing during active GLP-1 treatment caught them early. Assumptions about nutritional status during a GLP-1 deficit are not reliable.
Protein requires active management, not passive intent.
Knowing that protein intake matters is not enough. GLP-1 appetite suppression makes under-eating protein the path of least resistance. Consistent tracking against a specific lean mass-adjusted target was required — not general awareness.
Lean mass data changes what you do.
Weekly BIA trend data and quarterly DEXA confirmation produced decisions that scale weight alone would not have triggered. Training adjustments, nutrition changes, and supplement responses were all calibrated against actual body composition data, not guesswork.
Resistance training is not optional in a GLP-1 deficit.
The clinical trial data on lean mass loss without resistance training during GLP-1 therapy is significant. The personal experience confirmed it. Structuring progressive overload consistently around GLP-1 energy and appetite patterns was the single most important variable in the lean mass preservation outcome.
Course corrections compound.
Each discovery — B12, iron, protein gap, training adjustment — produced a small improvement. No single change was transformative. The accumulation of small, data-informed corrections over 12 months produced the final outcome. Continuous tracking made continuous improvement possible.
The journey does not end at a target weight.
Reaching a body composition target is a milestone, not a finish line. Ongoing DEXA monitoring, regular bloodwork, and continued strength training remain the protocol. The tools that worked during the transformation are the same tools needed to maintain and build on it.
All lessons on this page are based on personal experience and general educational information. They are not medical advice, clinical recommendations, or a guide to any specific treatment protocol. Every person's situation is different. Consult your prescribing clinician, registered dietitian, and other qualified healthcare professionals before making any changes to your health management.
Section 5 — What comes next
THE JOURNEY CONTINUES.
Future DEXA scans
Regular DEXA scanning continues as part of the ongoing monitoring protocol. Scan results will be published to this page as the data record grows — with full transparency about what they show.
Ongoing bloodwork
B12, iron, ferritin, HbA1c, lipids, testosterone, and vitamin D will continue to be tested regularly. The biomarker monitoring cadence that identified early deficiencies remains part of the protocol.
Strength and body composition
Progressive resistance training continues. Key lift tracking and lean mass monitoring via smart scale BIA continue to be the weekly feedback mechanism. The goal has shifted from active fat loss to maintenance and strength development.
What will be published on this page as the journey continues
This page will be updated as data becomes available. All content is personal, educational, and informational only.
Data record
DEXA, BLOODWORK & PROGRESS DATA.
Published as data becomes available. All entries are personal and educational — not clinical documentation.
DEXA Result
Data will be published here
DEXA Scan 1 — Baseline
Whole-body composition, fat mass, lean mass, visceral fat area.
DEXA Result
Data will be published here
DEXA Scan 2 — 6 Month
First comparative data against baseline.
DEXA Result
Data will be published here
DEXA Scan 3 — 12 Month
Full journey documentation.
Biomarker Panel
Data will be published here
B12 & Iron Panel
Discovery of deficiency and monitoring of correction over time.
Biomarker Panel
Data will be published here
Metabolic Markers
HbA1c, fasting glucose, lipid panel trend over 12 months.
Strength Progress
Data will be published here
Key Lift Progression
Compound lift tracking across the fat loss phase — what held, what declined.
Body Composition
Data will be published here
Lean Mass Trend
Smart scale BIA weekly lean mass trend vs DEXA validation points.
Body Composition
Data will be published here
Protein Adherence
Weekly protein intake vs lean mass target — gap discovery and correction.
Body Composition
Data will be published here
Visceral Fat Area
DEXA-measured visceral fat reduction across three scan points.
All data shared is personal and educational in nature. It is not a recommendation for any specific approach. Individual outcomes vary. Consult your own healthcare professionals for personalised guidance.
JOIN THE JOURNEY.
NOT THE DESTINATION.
Founder Journey Sessions offer direct access to Ben — not as an expert with all the answers, but as someone navigating the same process with real data, ongoing DEXA scans, bloodwork results, and continuous learning. Sessions are educational conversations, not clinical consultations. Limited places available.
Pricing available in-app
Educational only
Founder Journey Sessions are educational conversations based on personal experience. They are not clinical consultations, coaching sessions, or medical advice.
Educational Use Only
Recomp Health provides educational and informational content only. The platform does not provide medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding medications, treatment decisions, and health concerns.